From Diagnosis to Drug Development
Update: 2025-10-16
Description
Chuck Scheper, Board Chair at Bexion Pharmaceuticals, shares how a stage IV non-Hodgkin lymphoma diagnosis at age 39 and a life-saving clinical trial led to his lifelong commitment to cancer research. He joins Tim Schroeder, CEO and Chairman of CTI, to discuss the founding of VaxCella, the evolution of cancer therapies, the importance of patient-centered research, and the role of collaboration in advancing drug development, highlighting resilience, innovation, and the impact of clinical trials.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
